The perception of music requires coordinated neural activities in distributed multi-functional centers across both hemispheres. The association between musical abilities and other general cognitive functions have been studied in several populations with inconsistent results.
The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials.
The purpose of this study is to compare abdominal weight gain and fat distribution to changes in brain morphology in people taking antipsychotic medications.
CFDI STUDY with ENZYME REPLACEMENT THERAPY (ERT)
Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60.
Parkinson's Disease (PD) is a progressive neurodegenerative disorder without a cure. While the search for a cure continues, there is a growing interest in psychiological approaches to manage distress in PD. The main objective of this study is to investigate various clinical outcomes in PD associated with different coping styles. Findings from this study will form the basis for projects aimed at designing interventions to foster beneficial coping styles and studies into the neural underpinnings of coping.
This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the standard conventional high frequency left sided stimulation protocol. The Left dorsolateral prefrontal cortex will be the site of stimulation in both treatment conditions. The site of stimulation will be targeted using MRI co-registration.
The objectives of this 15-day study are:
The purpose of this study is to collect brain scans, blood samples, memory test scores and cerebrospinal fluid from people with Alzheimer's disease (AD), mild cognitive impairment or no memory impairment. The information collected in the study may help characterize the early stages of AD, and shape the criteria for earlier diagnosis and treatment of AD. It will also be used to discover, standardize and validate measures and biomarkers that are used in AD research. The ADNI4 study is a continuation of the ADNI3 study and will also open to enroll new participants.
The purpose of this study is to evaluate the feasibility of using repetitive transcranial magnetic stimulation (rTMS) to treat depression.
The purpose of this study is to is to examine the effects of 12 weeks of high-intensity interval training on the cognitive health of perimenopausal women.
The purpose of this study is to explore the use of bright light therapy as maintenance treatment for depression to determine if it is
The purpose of this study is to learn about biomarkers (biological features such as proteins, genes, and brain images that indicate the state of a disease in a person), and how they can help predict treatment outcomes in patients with clinical depression.
The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).
The purpose of this study is to assess the safety and tolerability of valbenazine for the treatment of chorea associated with Huntington's Disease.
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.
There is a new theory that Parkinson's disease may start in the gut, but research is limited. The purpose of this study is to better understand the association between Parkinson's disease and the bacteria and fungi living in the gut and nose.
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment
MS is a disabling neurological disease with a highly variable clinical course including acute disability (relapses when symptoms appear or worsen) and disease progression (steady accumulation of disability in the absence of relapses). There is currently no approved treatment for progressive MS. A principal pathology of MS is the destruction of myelin, which surrounds nerves to speed up signal conduction. We have developed a magnetic resonance imaging technique that provides quantitative measurements of myelin.